Copyright © 1995 by the European Society of Cardiology.
© 1995 The European Society of Cardiology
Epidemiology of Fibrinogen
Division of Epidemiology, School of Public Health, University of Minnesota Minneapolis, U.S.A.
Correspondence. A. R. Folsom, Division of Epidemiology, School of Public Health, University of Minnesota, Suite 300, 1300 South Second Street, Minneapolis, MN 55454-1015, U.S.A.
As evidence accumulates to implicate fibrinogen as a risk factor for cardiovascular disease (CVD) it becomes important to characterize the levels and correlates of fibrinogen in diverse populations. Knowledge of the correlates of fibrinogen may help researchers to disentangle the independent contribution of elevated fibrinogen concentrations to CVD. Characterization of the normal range and possible determinants of fibrinogen concentrations, likewise, may aid CVD risk assessment and intervention research.
Fibrinogen concentrations vary widely among populations and increase with age. Levels are consistently higher in women than men and rise after menopause. Smoking is the most important lifestyle correlate of fibrinogen. People with diabetes and hypertension have elevated fibrinogen levels, as do sedentary and obese individuals. Alcohol intake and oestrogen replacement therapy are associated with lower fibrinogen levels. Most other CVD risk factors are correlated positively with fibrinogen.
Fibrinogen is clearly a marker of CVD risk. Yet, the strikingly non-specific pattern of higher fibrinogen with every CVD risk factor suggests that proving an independent causal role of fibrinogen will remain elusive in the absence of trials selectively lowering fibrinogen with the aim of reducing CVD.
Key Words: Fibrinogen • epidemiology • cardiovascular risk • population correlates • lifestyle • cardiovascular disease
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Caso, I. Mileva, P. Kelly, H. Ahn, M. C. Gelato, and M. A. McNurlan Feeding Acutely Stimulates Fibrinogen Synthesis in Healthy Young and Elderly Adults J. Nutr., November 1, 2009; 139(11): 2032 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Associations of Plasma Fibrinogen Levels with Established Cardiovascular Disease Risk Factors, Inflammatory Markers, and Other Characteristics: Individual Participant Meta-Analysis of 154,211 Adults in 31 Prospective Studies: The Fibrinogen Studies Collaboration Am. J. Epidemiol., October 15, 2007; 166(8): 867 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Ganotakis, I. F. Gazi, J. A. Papadakis, I. A. Jagroop, D. R. Nair, and D. P. Mikhailidis The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 35 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 The Fibrinogen Studies Collaboration Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27 247 adults in 15 prospective studies Int. J. Epidemiol., December 1, 2006; 35(6): 1570 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. Mahadevan, M. Campbell, P. P. McKeown, and U. Bayraktutan Internal mammary artery smooth muscle cells resist migration and possess high antioxidant capacity Cardiovasc Res, October 1, 2006; 72(1): 60 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Fibrinogen Studies Collaboration* Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality: An Individual Participant Meta-analysis JAMA, October 12, 2005; 294(14): 1799 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Steg, L. Francois, B. Iung, D. Himbert, P. Aubry, P. Charlier, H. Benamer, L. J. Feldman, and J.-M. Juliard Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction Eur. Heart J., September 2, 2005; 26(18): 1831 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Johanson, Y. Fu, S. G. Goodman, M. Dellborg, P. W. Armstrong, M. W. Krucoff, L. Wallentin, and G. S. Wagner A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy Eur. Heart J., September 1, 2005; 26(17): 1726 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Papadakis, D. P. Mikhailidis, G. E. Vrentzos, A. Kalikaki, I. Kazakou, and E. S. Ganotakis Effect of Antihypertensive Treatment on PlasmaFibrinogen and Serum HDL Levelsin Patients with Essential Hypertension Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 139 - 146. [Abstract] [PDF]
|
|
|
|
 |
|
 B. J. Drew, R. M. Califf, M. Funk, E. S. Kaufman, M. W. Krucoff, M. M. Laks, P. W. Macfarlane, C. Sommargren, S. Swiryn, and G. F. Van Hare Practice Standards for Electrocardiographic Monitoring in Hospital Settings: An American Heart Association Scientific Statement From the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: Endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses Circulation, October 26, 2004; 110(17): 2721 - 2746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Johanson, T. Jernberg, G. Gunnarsson, B. Lindahl, L. Wallentin, and M. Dellborg Prognostic value of ST-segment resolution--when and what to measure Eur. Heart J., February 2, 2003; 24(4): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kawahito, H. Kitahata, K. Tanaka, J. Nozaki, and S. Oshita Dynamic QRS-complex and ST-segment monitoring by continuous vectorcardiography during carotid endarterectomy Br. J. Anaesth., February 1, 2003; 90(2): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jernberg, B. Lindahl, and L. Wallentin Continuous multilead ST-segment monitoring should be a part of the clinical routine Eur. Heart J., June 2, 2002; 23(12): 918 - 921. [Full Text] [PDF]
|
|
|
|
|
|
U Zeymer, R Schroder, U Tebbe, G.P Molhoek, K Wegscheider, and K.-L Neuhaus Non-invasive detection of early infarct vessel patency by resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction. Results of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trial Eur. Heart J., May 1, 2001; 22(9): 769 - 775. [Abstract] [PDF]
|
|